Catalent acquires gene therapy specialist Paragon for $1.2bn

05:42 EDT 17 Apr 2019 | pharmaphorum

Drug delivery technology provider Catalent is to acquire gene therapy company Paragon for $1.2 billion. Paragon specialises in adeno-associated virus (AAV) vectors, the most commonly used delivery system for gene therapy, as well as unique capabil...

Original Article: Catalent acquires gene therapy specialist Paragon for $1.2bn


More From BioPortfolio on "Catalent acquires gene therapy specialist Paragon for $1.2bn"

Quick Search


Relevant Topics

Drug Delivery
<!--LGfEGNT2Lhm-->Drug delivery is the method or process of administering a pharmaceutical compound to achieve a therapeutic effect in humans or animals.  <!--LGfEGNT2Lhm-->Drug delivery technologies are <!--LGfEGNT2Lhm-->patent pr...

Gene Therapy
Gene therapy is the use of DNA as a pharmaceutical agent to treat disease. It derives its name from the idea that DNA can be used to supplement or alter genes within an individual's cells as a therapy to treat disease. The most common form of gene th...

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...